Effects of Trifluoperazine on Doxorubicin Resistance
Author Information
Author(s): R. Ganapathi, H. Schmidt, D. Grabowski, M. Melia, N. Ratliff
Primary Institution: Research Institute, Cleveland Clinic Foundation
Hypothesis
The calmodulin inhibitor trifluoperazine modulates the cytotoxicity of doxorubicin in resistant melanoma cells.
Conclusion
Trifluoperazine enhances the effectiveness of doxorubicin in resistant melanoma cells without significantly altering drug accumulation.
Supporting Evidence
- Trifluoperazine did not cause significant cytotoxicity on its own.
- The combination of doxorubicin and trifluoperazine was more effective in reducing tumor burden in resistant cells.
- Cellular doxorubicin levels did not correlate with the degree of resistance.
Takeaway
This study shows that a drug called trifluoperazine can help make another drug, doxorubicin, work better against cancer cells that usually resist it.
Methodology
The study involved treating progressively doxorubicin-resistant B16-BL6 mouse melanoma cells with doxorubicin and trifluoperazine, assessing cytotoxicity, drug accumulation, and retention in vitro and in vivo.
Limitations
The study's findings may not fully translate to clinical settings due to the specific model used and the levels of drug resistance tested.
Participant Demographics
Male C57BL/6NCr mice, 6-8 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website